These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 18687023)

  • 41. The answerable question and a hierarchy of evidence.
    Hamilton J
    J Am Acad Child Adolesc Psychiatry; 2005 Jun; 44(6):596-600. PubMed ID: 15908843
    [No Abstract]   [Full Text] [Related]  

  • 42. [Drugs for attention deficit hyperactivity disorder].
    Montañés-Rada F; Gangoso-Fermoso AB; Martíínez-Granero MA
    Rev Neurol; 2009 May 1-15; 48(9):469-81. PubMed ID: 19396764
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Close up on atomoxetine: a nonstimulant choice for treating ADHD.
    Allen C; Pitcock J
    Adv Nurse Pract; 2006 Mar; 14(3):39-40, 42-3, 78. PubMed ID: 16548127
    [No Abstract]   [Full Text] [Related]  

  • 44. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.
    Kratochvil CJ; Heiligenstein JH; Dittmann R; Spencer TJ; Biederman J; Wernicke J; Newcorn JH; Casat C; Milton D; Michelson D
    J Am Acad Child Adolesc Psychiatry; 2002 Jul; 41(7):776-84. PubMed ID: 12108801
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder.
    Ozbaran B; Kose S; Yuzuguldu O; Atar B; Aydin C
    World J Biol Psychiatry; 2015; 16(8):619-24. PubMed ID: 26223958
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
    Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies.
    Fredriksen M; Halmøy A; Faraone SV; Haavik J
    Eur Neuropsychopharmacol; 2013 Jun; 23(6):508-27. PubMed ID: 22917983
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacologic mood destabilization: case vignettes.
    Swann AC
    CNS Spectr; 2009 Nov; 14(11 Suppl 11):9-11; discussion 12-4. PubMed ID: 20173695
    [No Abstract]   [Full Text] [Related]  

  • 49. Improving decision making in the treatment of ADHD.
    Vitiello B
    Am J Psychiatry; 2008 Jun; 165(6):666-7. PubMed ID: 18519529
    [No Abstract]   [Full Text] [Related]  

  • 50. Emotional expression during attention-deficit/hyperactivity disorders treatment: initial assessment of treatment effects.
    Kratochvil CJ; Faries D; Vaughan B; Perwien A; Busner J; Saylor K; Kaplan S; Buermeyer C; Swindle R
    J Child Adolesc Psychopharmacol; 2007 Feb; 17(1):51-62. PubMed ID: 17343553
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Atomoxetine and nonresponders to stimulants.
    Velcea G; Winsberg BG
    Am J Psychiatry; 2004 Sep; 161(9):1718-9. PubMed ID: 15337674
    [No Abstract]   [Full Text] [Related]  

  • 52. Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD.
    Starr HL; Kemner J
    J Natl Med Assoc; 2005 Oct; 97(10 Suppl):11S-16S. PubMed ID: 16350601
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Attention deficit hyperactivity disorder, tics and Tourette's syndrome: the relationship and treatment implications. A commentary.
    Robertson MM
    Eur Child Adolesc Psychiatry; 2006 Feb; 15(1):1-11. PubMed ID: 16514504
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006.
    Harpin VA
    Arch Dis Child Educ Pract Ed; 2008 Apr; 93(2):58-65. PubMed ID: 18356307
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
    Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E
    Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis.
    Hazell PL; Kohn MR; Dickson R; Walton RJ; Granger RE; Wyk GW
    J Atten Disord; 2011 Nov; 15(8):674-83. PubMed ID: 20837981
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Spontaneous Ejaculation Induced with Atomoxetine.
    Yaylacı F; Şahbudak B; Küçük Ö
    Psychopharmacol Bull; 2020 Mar; 50(1):40-43. PubMed ID: 32214521
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [What's new about hyperactivity disorder in children?].
    Le Heuzey MF
    Arch Pediatr; 2008 Jul; 15(7):1249-52. PubMed ID: 18485682
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
    Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P
    CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differences in Utilization Patterns among Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: a 36-Month Retrospective Study Using the Korean Health Insurance Review and Assessment Claims Database.
    Bhang SY; Hwang JW; Kwak YS; Joung YS; Lee S; Kim B; Sohn SH; Chung US; Yang J; Hong M; Bahn GH; Choi HY; Oh IH; Lee YJ
    J Korean Med Sci; 2016 Aug; 31(8):1284-91. PubMed ID: 27478341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.